-
1
المؤلفون: Shenhong Wu, Katja Schindler, Mario E. Lacouture, Kathryn Ciccolini, Johannah Valentine, Viswanath Reddy Belum, Juanita Duran
المصدر: Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosarioمصطلحات موضوعية: Web of science, Daclizumab, Dasatinib, Cetuximab, Antagonists and inhibitors, Tumor protein, Phase 1 clinical trial (topic), Antineoplastic agents, Medicine, Molecular targeted therapy, Fulvestrant, Alitretinoin, Incidence, Gefitinib, Enzyme inhibitor, Antineoplastic hormone agonists and antagonists, Cancer registry, Mek, Bevacizumab, Skin diseases, Antineoplastic agent, Erlotinib, Hdac, Molecularly targeted therapy, Neoplasm proteins, Cancer chemotherapy, Dermatologist, Age distribution, Human, medicine.medical_specialty, Vegfr, monoclonal, Anastrozole, Afatinib, Article, Crizotinib, Humans, Dosing, Everolimus, Phase 3 clinical trial (topic), Adverse effect, Trastuzumab emtansine, Xerosis, Raf, Clinical trial, Concomitant, Relative risk, Immunology, Cd20, Risk factor, Phase 2 clinical trial (topic), Complication, Axitinib, Exemestane, Skin manifestation, Bortezomib, Clinical trials, Quality of life, Randomized controlled trial (topic), Chemically induced, Neoplasms, Key words bcr-abl, Alemtuzumab, Priority journal, Incidence (epidemiology), Dabrafenib, Ibrutinib, Medline, Common Terminology Criteria for Adverse Events, Enzyme inhibitors, Bosutinib, Brentuximab vedotin, Controlled clinical trial (topic), Drug therapy, Denosumab, Monoclonal antibody, Risk, Dry skin, Hormone antagonist, Mtor, phase iii as topic, Dermatology, Ceritinib, Antibodies, Her2, Internal medicine, Cd52, Prospective study, business.industry, Adverse effects, Egfr, Carfilzomib, Hormone antagonists, Cabozantinib, Denileukin diftitox, phase ii as topic, hormonal, High risk patient, Medical society, Severity of illness index, Bexarotene, Systematic review, Cancer patient, Neoplasm, Ibritumomab tiuxetan, business, Unindexed drug, Prospective studies, Meta analysis
وصف الملف: application/pdf
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1748e8addf4299cdfd680ca2c0bd1f33
https://repository.urosario.edu.co/handle/10336/22471 -
2
المؤلفون: Steven Paul Nistico, Sergio Chimenti, Marina Papoutsaki, Annamaria Mazzotta, Antonio Costanzo
مصطلحات موضوعية: rheumatoid arthritis, Male, drug safety, psoriasis vulgaris, corticosteroid, cyclosporin, etanercept, methotrexate, retinoid, tumor necrosis factor, adult, body surface, clinical article, clinical trial, controlled clinical trial, controlled study, disease activity, disease severity, drug efficacy, drug tolerability, female, follow up, human, injection site, letter, male, open study, priority journal, side effect, skin manifestation, treatment outcome, urticaria, aged, clinical assessment, drug tolerance, drug withdrawal, laboratory test, monotherapy, psoriasis area and severity index, psoriatic arthritis, rating scale, Adult, Aged, Anti-Inflammatory Agents, Non-Steroidal, Female, Humans, Immunoglobulin G, Middle Aged, Psoriasis, Receptors, Tumor Necrosis Factor, Severity of Illness Index, Treatment Outcome, Tumor Necrosis Factor-alpha, Anti-Inflammatory Agents, Etanercept, Receptors, Medicine, Plaque psoriasis, Settore MED/35 - Malattie Cutanee e Veneree, Non-Steroidal, Efficacy Study, medicine.drug, medicine.medical_specialty, Dermatology, In patient, business.industry, business, Tumor Necrosis Factor
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dff580022ef87f5e1c4622905522e95f
http://hdl.handle.net/2108/33747